BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 01, 2004
 |  BioCentury  |  Product Development

Poly-nating the HCV space

The gaggle of companies developing oral polymerase inhibitors to treat HCV just got a little bigger, as Roche has signed with Pharmasset Inc. to develop PSI 6130, an oral nucleoside polymerase inhibitor in late preclinical development.

According to Abel De La Rosa, senior vice president of business development and strategy at Pharmasset, the companies plan to accelerate the program by running the remaining preclinical work on the compound in parallel.

Pharmasset has not disclosed any preclinical data and has no...

Read the full 400 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >